Abeona Therapeutics Accelerates Patient Demand for Groundbreaking Gene Therapy
Abeona Therapeutics has made significant strides in the fourth quarter of 2025, with its groundbreaking gene therapy, ZEVASKYN, experiencing growing patient demand. As reported during the company's recent conference call, ZEVASKYN was approved in April 2025 but had a delayed launch to quarter four due to optimization of a sterility test required for product release.
Dr. Vish Seshadri, Chief Executive Officer, highlighted that treating the first commercial patient this past December marked a significant milestone for Abeona, and the company is now focused on building a consistent cadence of biopsies, product delivery, and treatments. Since resuming manufacturing in late January after their annual shutdown, the company has treated one patient this quarter, biopsied three additional patients with treatments scheduled over the coming weeks, and expects to perform additional biopsies this month.
Notably, all patient treatments and biopsies performed to date have originated from two of their four qualified treatment centers (QTCs), Lurie Children's Hospital in Chicago and Lucile Packard Children's Hospital at Stanford. However, with the activation of their third and fourth QTCs, Children's Hospital of Colorado and UTMB at Galveston, Texas, the company anticipates a healthy cadence of patient biopsies in the coming months.
Dr. Madhav Vasanthavada, Chief Commercial Officer, elaborated on the commercial update during the conference call, stating that demand for ZEVASKYN continues to grow. The company has deployed a field team engaging with community physicians, which has led to an increase in identified eligible patients from nearly 50 to over 100. While the speed at which identified patients receive ZEVASKYN treatment has varied, the momentum is picking up, with two patients treated since launch and three additional biopsied for treatment.
Furthermore, Dr. Vasanthavada mentioned that no payers have denied insurance coverage for ZEVASKYN, reflecting its strong value to this patient community. Abeona Therapeutics recognizes the importance of providing a seamless experience for every patient in the ZEVASKYN treatment journey and is focused on ensuring operational excellence, particularly within the close-knit RDEB community.
The company's goal is to demonstrate that their operational machine behind ZEVASKYN works at scale from initial biopsy through final delivery. By achieving this, Abeona Therapeutics aims to catalyze organic demand needed to scale ZEVASKYN in 2026 and beyond. With its focus on patient experience, operational excellence, and growing demand for the gene therapy, Abeona Therapeutics is poised for significant growth in the coming year.
Abeona's commitment to delivering a smooth journey for RDEB patients aligns with the growing recognition that providing an exceptional patient experience is crucial for driving organic demand and scaling innovative treatments like ZEVASKYN. The company's efforts to build operational excellence resonate deeply within this close-knit community, where every patient matters.
The successful deployment of their field team has also led to a significant increase in identified eligible patients, demonstrating the growing interest in ZEVASKYN among medical professionals and patients alike. As Abeona continues to expand its reach and improve operational efficiency, it is poised to make a meaningful impact on the lives of those living with RDEB.
With an unwavering commitment to delivering exceptional patient care, Abeona Therapeutics stands at the forefront of innovation in gene therapy, paving the way for improved treatment outcomes and better quality of life for individuals affected by RDEB.
